BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 33300431)

  • 1. DCAF13 promotes triple-negative breast cancer metastasis by mediating DTX3 mRNA degradation.
    Liu J; Li H; Mao A; Lu J; Liu W; Qie J; Pan G
    Cell Cycle; 2020 Dec; 19(24):3622-3631. PubMed ID: 33300431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCAF13 promotes breast cancer cell proliferation by ubiquitin inhibiting PERP expression.
    Shan BQ; Wang XM; Zheng L; Han Y; Gao J; Lv MD; Zhang Y; Liu YX; Zhang H; Chen HS; Ao L; Zhang YL; Lu X; Wu ZJ; Xu Y; Che X; Heger M; Cheng SQ; Pan WW; Zhang X
    Cancer Sci; 2022 May; 113(5):1587-1600. PubMed ID: 35178836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin promotes breast cancer cell migration and invasion via DCAF13.
    Sun Z; Zhou D; Yang J; Zhang D
    FEBS Open Bio; 2022 Jan; 12(1):221-230. PubMed ID: 34775691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by targeting PTEN degradation.
    Zhang J; Zhang YL; Zhao LW; Pi SB; Zhang SY; Tong C; Fan HY
    Cell Mol Life Sci; 2020 Jun; 77(11):2181-2197. PubMed ID: 31492966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
    Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
    Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
    [No Abstract]   [Full Text] [Related]  

  • 7. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
    Luo N; Zhang K; Li X; Hu Y
    J Cell Biochem; 2020 Oct; 121(10):4176-4187. PubMed ID: 31922280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.
    Kim HY; Ha Thi HT; Hong S
    Cancer Lett; 2018 Feb; 415():30-39. PubMed ID: 29217458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
    Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
    Block CJ; Mitchell AV; Wu L; Glassbrook J; Craig D; Chen W; Dyson G; DeGracia D; Polin L; Ratnam M; Gibson H; Wu G
    Oncogene; 2021 Nov; 40(46):6430-6442. PubMed ID: 34608266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer.
    Fan Y; Wang J; Jin W; Sun Y; Xu Y; Wang Y; Liang X; Su D
    Mol Cancer; 2021 Feb; 20(1):25. PubMed ID: 33530981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H; Sang M; Liu F; Ai N; Geng C
    Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
    Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
    Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma.
    Wei S; Xing J; Chen J; Chen L; Lv J; Chen X; Li T; Yu T; Wang H; Wang K; Yu W
    J Exp Clin Cancer Res; 2024 Jan; 43(1):3. PubMed ID: 38163876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function and prognosis analysis of nucleolus protein DCAF13 in breast cancer.
    Wang M; Fu L; Tian J; Zhang Y; Rossi L; Wang K
    Transl Cancer Res; 2023 Dec; 12(12):3744-3751. PubMed ID: 38197079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
    Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
    Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-300 Regulates the Ubiquitination of PTEN through the CRL4B
    Chen Z; Zhang W; Jiang K; Chen B; Wang K; Lao L; Hou C; Wang F; Zhang C; Shen H
    Mol Ther Nucleic Acids; 2018 Mar; 10():254-268. PubMed ID: 29499938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.
    Yue CH; Liu JY; Chi CS; Hu CW; Tan KT; Huang FM; Pan YR; Lin KI; Lee CJ
    Anticancer Res; 2019 Aug; 39(8):4149-4164. PubMed ID: 31366500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.